Company & Sponsor Intelligence

InSightec

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →
Indexed trials8
Recruiting5
Completed3
Countries4

Therapeutic footprint

alzheimersparkinsons

Indexed studies

NCT03671889ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
alzheimers · United StatesNA
NCT03319485ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
parkinsons · United StatesNA
NCT05539196A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
parkinsons · United StatesRECRUITING
NCT02246374ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
parkinsons · United StatesNA
NCT03454425A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
parkinsons · SpainNA
NCT07764874Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
parkinsons · South KoreaNA
NCT04002596Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
parkinsons · JapanNA
NCT03100474Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
parkinsons · United StatesACTIVE_NOT_RECRUITING

Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →